Trials / Completed
CompletedNCT04430842
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Quadriga Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers with high LAT1 expression. The MTD of QBS10072S will be confirmed in patients with relapsed or refractory grade 4 astrocytoma.
Conditions
- Astrocytoma
- Brain Cancer
- Brain Metastases
- Bladder Cancer
- Breast Cancer
- Cervical Cancer
- Cholangiocarcinoma
- Colorectal Cancer
- Esophagus Cancer
- Gastric Cancer
- Head and Neck Cancer
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Melanoma
- Ovarian Cancer
- Pancreatic Cancer
- Pleural Mesothelioma
- Prostate Cancer
- Sarcoma
- Tongue Cancer
- Thymic Carcinoma
- Urinary Tract Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QBS10072S | QBS10072S targets cancers with high LAT1 expression. |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2022-09-21
- Completion
- 2022-12-22
- First posted
- 2020-06-12
- Last updated
- 2023-01-18
Locations
2 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT04430842. Inclusion in this directory is not an endorsement.